BioSpace News Archive

The PPD clinical research business of Thermo Fisher Scientific, the world leader in serving science, has been distinguished for industry leadership in digital and decentralized clinical trial solutions by Information Services Group (ISG), a leading global technology research and advisory firm.

Bellerophon Therapeutics, Inc. announced a poster presentation at the upcoming American Thoracis Society 2022 International Conference, being held May 13-18, 2022, in San Francisco, CA.

MedX Health Corp. is pleased to announce the signing of a commercial distribution agreement with Makromed/Arhan Global A.Ş following the conclusion of its successful paid pilot project.

Blue Water Vaccines Inc. announced that Erin Henderson, Chief Business Officer of Blue Water Vaccines, will present at the H.C. Wainwright Global Investment Conference.

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the three months ending March 31, 2022.

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported additional results from the SEAL study evaluating the abuse potential of ADAIR.

Quotient Limited, a commercial-stage diagnostics company, announced that it will host a key opinion leader webinar on the current landscape and unmet needs within blood grouping and donor disease screening on Monday, May 23, 2022 at 11:00am ET.

Aadi Bioscience, Inc. announced financial results for the first quarter of 2022 and provided a corporate update.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended March 31, 2022.

Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP).